{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T16:29:28Z","timestamp":1769012968960,"version":"3.49.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.leukres.2018.11.003","type":"journal-article","created":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T22:12:45Z","timestamp":1542060765000},"page":"50-57","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: A retrospective nationwide study in Japan"],"prefix":"10.1016","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1438-3623","authenticated-orcid":false,"given":"Hidehiro","family":"Itonaga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Ota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirohumi","family":"Taji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itsuto","family":"Amano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuo","family":"Ichinohe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Tanizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7455-5824","authenticated-orcid":false,"given":"Takeshi","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.leukres.2018.11.003_bib0005","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.leukres.2018.11.003_bib0010","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/leu.2008.119","article-title":"The myelodysplastic\/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features","volume":"22","author":"Orazi","year":"2008","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.leukres.2018.11.003_bib0015","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/blood-2014-02-553800","article-title":"Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic\/myeloproliferative neoplasms","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2018.11.003_bib0020","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/bjh.13600","article-title":"Chronic neutrophilic leukaemia and plasma cell-related neutrophilic leukaemoid reactions","volume":"171","author":"Bain","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.leukres.2018.11.003_bib0025","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1046\/j.1365-2141.1996.7082329.x","article-title":"Chronic neutrophil leukaemia in adolescence and young adulthood","volume":"94","author":"Hasle","year":"1996","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.leukres.2018.11.003_bib0030","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF01715131","article-title":"Chronic neutrophilic leukemia. A study of four cases","volume":"68","author":"Zittoun","year":"1994","journal-title":"Ann. Hematol."},{"issue":"11","key":"10.1016\/j.leukres.2018.11.003_bib0035","first-page":"1566","article-title":"Identification of risk factors in atypical chronic myeloid leukemia","volume":"91","author":"Breccia","year":"2006","journal-title":"Haematologica"},{"issue":"April (4)","key":"10.1016\/j.leukres.2018.11.003_bib0040","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1023\/A:1008393002748","article-title":"Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia","volume":"11","author":"Hern\u00e1ndez","year":"2000","journal-title":"Ann. Oncol."},{"issue":"June (11","key":"10.1016\/j.leukres.2018.11.003_bib0045","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1200\/JCO.2001.19.11.2915","article-title":"BCR rearrangement-negative chronic myelogenous leukemia revisited","volume":"19","author":"Kurzrock","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2018.11.003_bib0050","first-page":"205","article-title":"Philadelphia-negative (Ph-) chronic myeloid leukemia (CML): comparison with Ph+ CML and chronic myelomonocytic leukemia","volume":"78","author":"Martiat","year":"1991","journal-title":"The Groupe Fran\u00e7ais de Cytog\u00e9n\u00e9tique H\u00e9matologique. Blood"},{"issue":"4","key":"10.1016\/j.leukres.2018.11.003_bib0055","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/BF02982088","article-title":"Severe bleeding tendency caused by leukemic infiltration and destruction of vascular walls in chronic neutrophilic leukemia","volume":"74","author":"Noguchi","year":"2001","journal-title":"Int. J. Hematol."},{"issue":"19","key":"10.1016\/j.leukres.2018.11.003_bib0060","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1214514","article-title":"Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML","volume":"368","author":"Maxson","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.leukres.2018.11.003_bib0065","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/leu.2013.122","article-title":"CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia","volume":"27","author":"Pardanani","year":"2013","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.leukres.2018.11.003_bib0070","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ng.2495","article-title":"Recurrent SETBP1 mutations in atypical chronic myeloid leukemia","volume":"45","author":"Piazza","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.leukres.2018.11.003_bib0075","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13045-014-0077-1","article-title":"CSF3R, SETBP1 and CALR mutations in chronic neutrophilic leukemia","volume":"7","author":"Cui","year":"2014","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2018.11.003_bib0080","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1023\/A:1008393002748","article-title":"Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia","volume":"11","author":"Hern\u00e1ndez","year":"2000","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2018.11.003_bib0085","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/ajh.24983","article-title":"Chronic neutrophilic leukemia: 2018 update on diagnosis, molecular genetics and management","volume":"93","author":"Elliott","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"7","key":"10.1016\/j.leukres.2018.11.003_bib0090","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1182\/blood-2016-08-693630","article-title":"How I treat atypical chronic myeloid leukemia","volume":"129","author":"Gotlib","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2018.11.003_bib0095","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.3109\/10428194.2014.986477","article-title":"Efficacy and side-effects of decitabine in treatment of atypical chronic myeloid leukemia","volume":"56","author":"Tong","year":"2015","journal-title":"Leuk. Lymphoma"},{"issue":"6","key":"10.1016\/j.leukres.2018.11.003_bib0100","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1177\/1078155215605662","article-title":"Activity of single-agent decitabine in atypical chronic myeloid leukemia","volume":"22","author":"Hausmann","year":"2016","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"2","key":"10.1016\/j.leukres.2018.11.003_bib0105","first-page":"67","article-title":"Significant clinical response to JAK1\/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia","volume":"3","author":"Dao","year":"2014","journal-title":"Leuk. Res. Rep."},{"issue":"5","key":"10.1016\/j.leukres.2018.11.003_bib0110","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00277-014-2272-0","article-title":"Atypical chronic myeloid leukemia with concomitant CSF3R T618I and SETBP1 mutations unresponsive to the JAK inhibitor ruxolitinib","volume":"94","author":"Ammatuna","year":"2015","journal-title":"Ann. Hematol."},{"issue":"12","key":"10.1016\/j.leukres.2018.11.003_bib0115","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/cncr.29986","article-title":"Activity of the oral mitogen-activated protein kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies","volume":"122","author":"Borthakur","year":"2016","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.leukres.2018.11.003_bib0120","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/sj.bmt.1704472","article-title":"Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative\/BCR-ABL-negative chronic myelogenous leukemia","volume":"33","author":"Mittal","year":"2004","journal-title":"Bone Marrow Transplant."},{"issue":"12","key":"10.1016\/j.leukres.2018.11.003_bib0125","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/sj.bmt.1704686","article-title":"Outcome of hematopoietic stem cell transplantation in patients with atypical chronic myeloid leukemia","volume":"34","author":"Koldehoff","year":"2004","journal-title":"Bone Marrow Transplant."},{"issue":"1","key":"10.1016\/j.leukres.2018.11.003_bib0130","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1111\/j.1751-553X.2011.01351.x","article-title":"Clinical course and molecular features in 21 patients with atypical chronic myeloid leukemia","volume":"34","author":"Koldehoff","year":"2012","journal-title":"Int. J. Lab. Hematol."},{"issue":"6","key":"10.1016\/j.leukres.2018.11.003_bib0135","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/bmt.2014.35","article-title":"The CSF3R T618I mutation as a disease-specific marker of atypical CML post allo-SCT","volume":"49","author":"Langabeer","year":"2014","journal-title":"Bone Marrow Transplant."},{"issue":"3","key":"10.1016\/j.leukres.2018.11.003_bib0140","doi-asserted-by":"crossref","first-page":"178","DOI":"10.5045\/br.2013.48.3.178","article-title":"Allogeneic hematopoietic cell transplantation in adult patients with myelodysplastic\/myeloproliferative neoplasms","volume":"48","author":"Lim","year":"2013","journal-title":"Blood Res."},{"issue":"January (1)","key":"10.1016\/j.leukres.2018.11.003_bib0145","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12185-015-1894-x","article-title":"Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data)","volume":"103","author":"Atsuta","year":"2016","journal-title":"Int. J. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2018.11.003_bib0150","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s12185-015-1907-9","article-title":"Scripts for TRUMP data analyses. Part II (HLA-related data): statistical analyses specific for hematopoietic stem cell transplantation","volume":"103","author":"Kanda","year":"2016","journal-title":"Int. J. Hematol."},{"issue":"3","key":"10.1016\/j.leukres.2018.11.003_bib0155","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1532\/IJH97.06239","article-title":"Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System","volume":"86","author":"Atsuta","year":"2007","journal-title":"Int. J. Hematol."},{"issue":"8","key":"10.1016\/j.leukres.2018.11.003_bib0160","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1182\/blood-2008-03-147041","article-title":"Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia","volume":"113","author":"Atsuta","year":"2009","journal-title":"Blood."},{"issue":"12","key":"10.1016\/j.leukres.2018.11.003_bib0165","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.3324\/haematol.2016.149427","article-title":"Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups","volume":"101","author":"Inamoto","year":"2016","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.leukres.2018.11.003_bib0170","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3324\/haematol.2015.136903","article-title":"High-risk HLA alleles for severe acute graft-versus-host disease and mortality in unrelated donor bone marrow transplantation","volume":"101","author":"Morishima","year":"2016","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.leukres.2018.11.003_bib0175","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","article-title":"Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research","volume":"15","author":"Giralt","year":"2009","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"12","key":"10.1016\/j.leukres.2018.11.003_bib0180","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Bone Marrow Transplant."},{"issue":"6","key":"10.1016\/j.leukres.2018.11.003_bib0185","first-page":"825","article-title":"1994 consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant."},{"issue":"3","key":"10.1016\/j.leukres.2018.11.003_bib0190","first-page":"250","article-title":"Chronic graft-versus-host disease and other late complications of bone marrow transplantation","volume":"28","author":"Sullivan","year":"1991","journal-title":"Semin. Hematol."},{"issue":"12","key":"10.1016\/j.leukres.2018.11.003_bib0195","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2014-10-607341","article-title":"An international consortium proposal of uniform response criteria for myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN) in adults","volume":"125","author":"Savona","year":"2015","journal-title":"Blood."},{"issue":"3","key":"10.1016\/j.leukres.2018.11.003_bib0200","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software\u2019 EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant."},{"issue":"5","key":"10.1016\/j.leukres.2018.11.003_bib0205","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1365-2141.2004.04955.x","article-title":"Chronic Leukemia Study Writing Committee of the International Bone Marrow Transplant Registry. Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants","volume":"125","author":"Passweg","year":"2004","journal-title":"Br. J. Haematol."},{"issue":"20","key":"10.1016\/j.leukres.2018.11.003_bib0210","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.1002\/cncr.24531","article-title":"Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis","volume":"115","author":"Gratwohl","year":"2009","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.leukres.2018.11.003_bib0215","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1182\/blood-2010-09-308510","article-title":"Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase","volume":"117","author":"Jiang","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2018.11.003_bib0220","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2141.2011.09009.x","article-title":"Risk models predicting survival after reduced-intensity transplantation for myelofibrosis","volume":"157","author":"Alchalby","year":"2012","journal-title":"Br. J. Haematol."},{"issue":"21","key":"10.1016\/j.leukres.2018.11.003_bib0225","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1182\/blood-2014-10-608315","article-title":"Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis","volume":"125","author":"Kr\u00f6ger","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2018.11.003_bib0230","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/bjh.13576","volume":"171","author":"Symeonidis","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.leukres.2018.11.003_bib0235","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.bbmt.2017.01.078","article-title":"Allogeneic hematopoietic cell transplantation for adult chronic myelomonocytic leukemia","volume":"23","author":"Liu","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"4","key":"10.1016\/j.leukres.2018.11.003_bib0240","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.bbmt.2017.11.016","article-title":"Prognostic impact of donor source on allogeneic hematopoietic stem cell transplantation outcomes in adults with chronic myelomonocytic leukemia: a nationwide retrospective analysis in Japan","volume":"24","author":"Itonaga","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"5","key":"10.1016\/j.leukres.2018.11.003_bib0245","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/ejh.12073","article-title":"Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire","volume":"90","author":"Park","year":"2013","journal-title":"Eur. J. Haematol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212618304648?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212618304648?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:59:40Z","timestamp":1758934780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212618304648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":49,"alternative-id":["S0145212618304648"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2018.11.003","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: A retrospective nationwide study in Japan","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2018.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}